Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Clarity Pharmaceuticals Ltd. ( (AU:CU6) ).
Clarity Pharmaceuticals has successfully completed recruitment for its Co-PSMA trial, which evaluates the performance of its diagnostic product, 64Cu-SAR-bisPSMA, against the standard-of-care 68Ga-PSMA-11 in detecting prostate cancer recurrence. The trial aims to address the need for more sensitive diagnostic tools for patients with low PSA levels following radical prostatectomy. Positive results from previous trials have led to ongoing Phase III trials, potentially improving image-guided therapy and patient outcomes.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$7.40 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company focused on developing next-generation products to improve cancer treatment outcomes. The company specializes in Targeted Copper Theranostics (TCTs) and utilizes its proprietary SAR technology to securely hold copper isotopes for diagnostic and therapeutic purposes.
Average Trading Volume: 2,897,413
Technical Sentiment Signal: Hold
Current Market Cap: A$989.6M
For a thorough assessment of CU6 stock, go to TipRanks’ Stock Analysis page.